Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site […]
Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese […]
Novo Nordisk’s semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.
Nitinotes Ltd. has begun patient enrollment in its pivotal U.S. Investigational Device Exemption study evaluating the EndoZip Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The first procedure in the EASE Clinical Trial was completed at Lenox Hill Hospital | Northwell Health in New York, marking the U.S. debut of the device. This study pits […]
Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by […]
